Summary of Lifesaving Drugs Could Be Made Accessible to All:
A recent study conducted by the London School of Hygiene & Tropical Medicine (LSHTM) has found that tranexamic acid (TXA), a drug used to treat severe post-childbirth bleeding, can be safely administered intramuscularly and reach therapeutic levels quickly. The study also found that oral administration of TXA is well-tolerated but takes longer to reach therapeutic levels. Providing TXA through multiple routes, including intramuscular and oral, can make this lifesaving treatment more accessible to women globally, especially in low and middle-income countries where healthcare facilities may be limited, or births often occur at home. Severe bleeding after childbirth, or postpartum hemorrhage, is a leading cause of maternal death worldwide, particularly in low and middle-income countries. The study’s findings provide enough evidence to conduct further clinical trials to evaluate the effectiveness of intramuscular administration of TXA in reducing postpartum bleeding.
*****
Summary Bullet Points:
– A recent study has shown that tranexamic acid (TXA), a drug used to treat severe post-childbirth bleeding, can be safely administered intramuscularly and orally, making it more accessible to women globally.
– Severe postpartum hemorrhage (PPH) is a leading cause of maternal death, particularly in low- and middle-income countries (LMICs).
– The Woman-PharmacoTXA Phase 2 trial demonstrated that intramuscular TXA quickly achieves adequate therapeutic levels and is well-tolerated, providing an alternative to intravenous administration.
– Oral TXA is also well-tolerated but takes longer to reach therapeutic blood concentrations, making it less suitable for emergency treatment.
– These findings support the need for comparative Phase 3 clinical trials to determine the effectiveness of intramuscular administration in reducing postpartum bleeding.
Article:
When it comes to women’s health, one area of concern that stands out is severe postpartum hemorrhage (PPH). This condition, characterized by severe bleeding after childbirth, is a leading cause of maternal death worldwide. Sadly, the majority of these deaths occur in low- and middle-income countries (LMICs), where access to healthcare facilities may be limited. However, a recent study has shed light on a potential solution that could make a lifesaving treatment more accessible to all women.
The study, known as the Woman-PharmacoTXA Phase 2 trial, focused on tranexamic acid (TXA), a drug typically used to treat severe bleeding during and after surgery. Researchers from the London School of Hygiene & Tropical Medicine (LSHTM) and collaborating countries explored the safety and effectiveness of administering TXA intramuscularly rather than through the prevalent intravenous method. This alternative approach could prove vital in situations such as home births or remote healthcare environments where intravenous administration may be impractical.
The trial involved recruiting over 120 women aged 18 or older who were due to give birth via cesarean section. The participants were from two hospitals in Pakistan and one in Zambia, representing LMICs. All the women had one or more risk factors for postpartum hemorrhage, making them ideal candidates for the study.
Results from the trial indicated that intramuscular administration of TXA was well-tolerated and quickly achieved adequate therapeutic levels in the blood. This method reached the necessary concentrations within ten minutes of injection and maintained them for over four hours. Such findings are promising, as they suggest that intramuscular TXA could be a viable alternative to intravenous administration.
Another route of administration that was explored in the trial was oral TXA. While this method was also well-tolerated, it took around one hour for the drug to reach therapeutic blood concentrations. Consequently, oral TXA may not be suitable for emergency treatment, but it could still play a crucial role in non-emergency cases.
The significance of these findings cannot be understated, particularly in LMICs. In many of these countries, women give birth at home, with limited access to healthcare facilities. If TXA can be administered intramuscularly as effectively as through intravenous injection, it could have a profound impact on reducing the number of deaths caused by postpartum hemorrhage. The study’s co-authors emphasize the importance of providing options for TXA administration, especially in regions where intravenous canulation may not be feasible.
Professor Haleema Shakur-Still, a co-author and Professor of Global Health Clinical Trials at LSHTM, highlights the potential impact of intramuscular TXA. She states, “If TXA can be given just as successfully intramuscularly as via intravenous injection, this could be of huge significance to the thousands of women who die every year from PPH.”
Furthermore, Professor Rizwana Chaudhri, another co-author based at Shifa Tameer-e-Millat University in Pakistan, emphasizes the practicality of the intramuscular route in her country. She explains, “The intramuscular route will be beneficial in Pakistan. With some patients who are experiencing a PPH, it is difficult to get an intravenous line established, so anything that can reduce PPH will be useful.”
Dr. Mwansa Ketty Lubeya, the study’s co-author from The University of Zambia-School of Medicine, Women and Newborn Hospital-UTH, also acknowledges the challenges faced in her country and expresses enthusiasm for the intramuscular option. She states, “In Zambia, we are still struggling with access to TXA. Even when it is available, there should be options in terms of administration. There is no point in having TXA when canulation is not an option. We are excited to have the intramuscular option and be able to use it far and wide.”
The positive outcomes of the Woman-PharmacoTXA Phase 2 trial have paved the way for further research and clinical trials. The researchers believe that conducting comparative Phase 3 trials, known as the I’M WOMAN trial, will provide additional evidence regarding the effectiveness of intramuscular administration in reducing postpartum bleeding. These upcoming trials, set to begin in August of this year, aim to determine if the intramuscular route is as effective as intravenous administration.
Dr. Ian Roberts, a co-author, and Professor of Epidemiology at LSHTM, shares his optimism about the potential of intramuscular administration. He states, “We have good reason to believe the intramuscular route will be as effective as the intravenous route to reduce postpartum bleeding. In August, we are starting a large global trial to prove this in the hope that this will change WHO guidelines. We want to make this lifesaving treatment available to all women wherever they give birth.”
In conclusion, the recent study on tranexamic acid administration provides hope for a practical and accessible solution to severe postpartum hemorrhage. By exploring alternative routes, such as intramuscular and oral administration, researchers have shown that TXA can be safely and effectively administered to pregnant women. These findings offer new possibilities for women in LMICs, where healthcare facilities may be scarce or where births frequently occur at home. The upcoming I’M WOMAN Phase 3 trials will reveal whether intramuscular administration is as effective as the standard intravenous method, potentially leading to changes in WHO guidelines. The goal is to ensure this lifesaving treatment becomes available to all women, regardless of their birthing circumstances. Through continued research and innovation, we can make significant strides in improving maternal health globally.
